The industry is significantly focused on the implications of next April's 'catch-up' statutory price reductions but it might need to take a wider view of what are much broader and fundamental changes to the policy infrastructure of the PBS that will have an enduring impact.
Companies hit hard by the new price cut 'flow on' mechanism
August 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Former Medicines NZ chair says the time for talk on Pharmac is over
December 5, 2023 - - Latest News -
Ex-TGA head John Skerritt appointed to Medicines Australia board
December 5, 2023 - - BioPharma -
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 - - Australian Biotech -
National Pharmacies opens its first 24-7 pharmacy under South Australian initiative
December 4, 2023 - - Latest News -
PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
December 4, 2023 - - Australian Biotech -
OncoSil Medical onboards first patient in the PANCOSIL clinical trial
December 4, 2023 - - Australian Biotech -
Korean regulator approves Amplia Therapeutics' pancreatic cancer trial
December 4, 2023 - - Australian Biotech